FY2025 · ended Dec 31, 2025 · Revenue $216.10M, +8.7% YoY · Filed Feb 12, 2026
Vanda Pharmaceuticals Inc. (VNDA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $216.1 million and a net loss of $220.5 million. Free cash flow was -$110.4 million. As of Sep 30, 2026 it held $61.9 million in cash and investments and $22.0 million in total debt.
Revenue (TTM)
$229.28M
+8.1% vs year-ago TTM
Net income (TTM)
$-274.83M
-226.4% vs year-ago TTM
Operating cash flow (TTM)
$-139.14M
-70.0% vs year-ago TTM
Free cash flow (TTM)
$-139.96M
-68.7% vs year-ago TTM
EPS (TTM)
$-4.59
-220.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
59.11M
+1.4% vs prior year
Net cash
$39.96M
as of Sep 30, 2026
Operating margin
-77.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M | $33.2M |
| Diluted EPS | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.58 |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M |
| Stockholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M |
| Cash and investments | $84.9M | $102.3M | $135.8M | $135.0M | $432.8M |
| Total debt | $12.6M | $12.4M | $9.4M | $11.1M | $12.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1000 Vanda Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.